REPLICEL LIFE SCIENC (OTC BB: REPCF.OB )
Started tracking REPCF Friday afternoon after it caught my eye. REPCF is starting to show positive signs. It is still a little thin, but i see some promise here. The 52 week range is 0.25 X 4.00. In February, it was trading @ $2.00 and under. Its been slowly climbing since and on Friday it closed out at $2.90 a share with a 16% gain. It also has saw some nice attention on Friday with a volume of 45,162 ($119,749 In Traded Value) compared to the average volume ( 3m ) of 2,670. I expect to see some profit taking, but believe it is still worth placing it on your Watch List IMO. Stay Alert !
According to Medem Medical Library's website, male pattern baldness (MPB) affects roughly 40 million men in the United States. Approximately 25 percent of men
begin balding by age 30; two-thirds begin balding by age 60. There is a 4 in 7 chance of getting the baldness gene[1] Male pattern is characterized by hair receding from the lateral sides of the forehead, known as a "receding hairline". Receding hairlines are usually seen in males above the ages of 20 but can be seen as early as late teens as well.
Business Description
RepliCel Life Sciences Inc. has developed RepliCel, a natural hair cell replication technology that has the potential to become the world's first, minimally invasive solution for androgenetic alopecia (pattern baldness) and general hair loss in men and women. RepliCel is based on autologous cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles and, when reintroduced into areas of hair loss, the Company hopes to initiate natural hair regeneration. Patents for the technology have been issued by the European Union and Australia and are pending in other major international jurisdictions. The RepliCel procedure has been developed over the past nine years by the Company's recognized research scientists and medical experts - specialists in the fields of hair growth, hair biology and dermatology.
Latest News Release - RepliCel Injects Final Patient with Hair Follicle Cells in its First-In-Man Clinical Trial TS001-2009
VANCOUVER, BRITISH COLUMBIA--(Marketwire -09/07/11)- RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTC.BB: REPCF.OB - News) is pleased to report that the final study participant has received injections of hair follicle cells prepared using RepliCel™ technology. This milestone marks the end of the treatment phase of the TS001-2009 clinical trial in which a total of nineteen participants received injections. To date, no serious adverse events have been reported post-injection. Please note that recruitment of subjects was closed at nineteen (rather than the planned twenty) to allow for timely processing of interim analysis data from the six-month follow-up time point. This interim analysis is scheduled to take place in Q1, 2012.
In the next stage of the TS001-2009 trial, the post-injection follow-up period, subjects return to the study centre to have their health closely monitored to ensure that there have been no adverse effects associated with receiving the injections and to determine the hair growth stimulating efficacy of the hair follicle cell injections.
Once the final patient has completed their six-month follow-up visit, an interim analysis of all collected data will be performed to assess the primary outcome measure of the TS001-2009 study. The analysis will involve assessment of the local (at treatment sites) safety profile of autologous hair follicle cells compared to placebo as defined by AEs with respect to their causality, incidence, severity and seriousness. Secondary outcome measures of systemic (overall) safety (through review of adverse events in a similar fashion as described above) and efficacy (hair growth at treatment sites) will also be performed at this time. Subjects will participate in the post-injection follow-up period of the study until August 2013 and final analysis of safety data should be available in late 2013.
TS001-2009 Clinical Trial Overview
The TS001-2009 clinical trial is designed to test the safety and efficacy of the RepliCel™ technology in men and women with androgenetic alopecia. This single-centre study enrolled subjects with alopecia categorized as either vertex pattern type II or type III on the Ludwig Scale (female) or as type III vertex to type VI on the Norwood Scale (male). At the beginning of the trial, subjects provided blood samples to confirm their health status and biopsies were taken from their scalps from which hair follicle cells were processed using RepliCel™ technology. Once cell processing was complete, subjects returned to the study centre to have baseline measurements of their overall health and the health of their scalps. They then received injections of their own replicated cells (autologous cells) in medium (verum) and medium alone (placebo) into two pre-selected treatment areas in their scalps.
In the post-injection follow-up period, subjects return to the clinic for 10 visits over the next 24 months. At these visits, subjects have their overall health assessed, as well as subjective and objective assessments of the areas that were injected either with verum or placebo. Digital images will be taken of the scalp to assess any changes to the scalp post-injection and the differences in health and hair growth between the two treatment areas. Furthermore, at 6, 12, and 24 months post-injection, four subjects at each time point will provide biopsies of the injection sites for histopathological analysis. The total duration of subject participation in the study is approximately 27 months.
Share Structure
Market Value
$117,595,017
a/o Sep 09, 2011
Shares Outstanding
40,550,006
a/o May 03, 2011
For More Information Visit Their Website @http://www.replicel.com/
Chart Link
http://bit.ly/p33oNy Any Feedback Appreciated.
All my posts and picks are purely my opinion. Use your own buy and sell signals and never invest in a stock you can not afford to lose money on.
